Protection efficacy of the rLTB-R1 chimera against experimental swine mycoplasmal pneumonia.

• Autor(a) principal: FERREIRA, M. R. A.
• Data de Publicação: 2019
• Outros Autores: FINGER, P. F., MAGALHÃES, C. G., CUNHA, C. E. P. da, MOREIRA JÚNIOR, C., KICH, J. D., MORES, M. A. Z., MOREIRA, A. N., DELLAGOSTIN, O. A., CONCEIÇÃO, F. R.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
• Texto Completo: http://www.alice.cnptia.embrapa.br/alice/handle/doc/1113965
• topic: Pneumonia micoplasmática suína; Vacinação mucosa; Adesina P97; LTB; Pneumonia; Micoplasma; Vacina; Suinocultura; Mycoplasma hyopneumoniae; Vaccination; Adhesins

Abstract: Mycoplasma hyopneumoniae is the etiological agent of the Swine Mycoplasmal Pneumonia (SMP), one of the most economically significant diseases in the swine industry worldwide. Commonly used vaccines for SMP control consist of inactivated whole cells (bacterins). These vaccines are efficacious against M. hyopneumoniae challenge, but do not prevent colonization by the pathogen or completely eliminate pneumonia. P97 adhesin is conserved in the M. pneumoniae virulent strains, therefore it is an attractive target to be used in recombinant vaccines against M. hyopneumoniae. The aim of the present study was to evaluate protection afforded by rLTB-R1, a recombinant chimera composed by LTB fused with the R1 repeat region of P97 adhesin of M. hyopneumoniae, in specific-pathogen-free (SPF) piglets vaccinated by intranasal or intramuscular route and challenged with a pathogenic strain of M. hyopneumoniae.